Search - tctmd.com

Displaying 41 - 60 of 1164

Sort: Relevancy | Date

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Yael L. Maxwell

April 29, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Daily News

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

L.A. McKeown

April 14, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

Cannabis Use Again Tied to Increased CVD Risk in Young People

L.A. McKeown

March 19, 2025

News Daily News

AHA Offers Help for Clinicians Weighing the Results of DTC Genetic Tests

Yael L. Maxwell

March 18, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2025

Shelley Wood

February 28, 2025

News Daily News

Can’t Exercise for a Cardiac Stress Test? That’s a Bad Sign

Todd Neale

February 25, 2025

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Advertisement

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Cardiotoxicity Rare With Common GI Chemotherapy

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Cannabis Use Again Tied to Increased CVD Risk in Young People

AHA Offers Help for Clinicians Weighing the Results of DTC Genetic Tests

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

TCTMD’s Top 10 Most Popular Stories for February 2025

Can’t Exercise for a Cardiac Stress Test? That’s a Bad Sign

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content